Biogen IDEC (NASDAQ:BIIB): Closing price $216.00
Biogen posted first-quarter earnings per share of $1.96, which was well above the Zacks Consensus Estimate of $1.57 and a 41 percent increase from the year-ago quarter. First quarter 2013 revenues rose by 10 percent to $1.415 billion, above the Zacks Consensus Estimate of $1.387 billion, with gains driven by Avonex and Tysabri. What is more, earnings were raised by roughly 17 cents thanks to a lower tax rate; if one-time items are counted, first quarter 2013 earnings increased by 43 percent to $1.79 per share.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.